Extended-spectrum beta-lactamases on the rise;Betalactamasas de espectro extendido en aumento

Revista Espanola de Quimioterapia

Volumn 18, Issue 2, 2005, Pages 115-117

  Gobernado, M ^a  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; BETA LACTAMASE; IMIPENEM; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM;

ABDOMINAL INFECTION; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC RESISTANCE; CATHETERIZATION; EDITORIAL; ESCHERICHIA COLI; HOSPITAL INFECTION; IMMUNE DEFICIENCY; KLEBSIELLA OXYTOCA; KLEBSIELLA PNEUMONIAE; PROTEUS MIRABILIS; CROSS INFECTION; HUMAN; MICROBIOLOGY; SPAIN;

BETA-LACTAM RESISTANCE; BETA-LACTAMASES; CROSS INFECTION; HUMANS; SPAIN;

EID: 23044442631     PISSN: 02143429     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (27)

1. Muñoz-Bellido, J.L. Betalactamasas de espectro extendido: ¿son hoy un serio problema en España? Rev Esp Quimioterap 2004; 14: 314-316.
2. Brun-Buisson, C., Legrand, P., Philippon, A., Montravers, F., Ansquer, M., Duval, J. Transferable enzymatic resistance to third-generation cephalosporins during nosocomial outbreak of multiresistant Klebsiella pneumoniae. Lancet 1987; ii: 302-306.
3. Fernández-Rodríguez, A., Reguera, J.A., Pérez-Díaz, J.C., Picazo, J.J., Baquero, F. Primera epidemia española de resistencia plasmídica a cefalosporinas de tercera generación: Implicación de SHV-2. Enferm Infecc Microbiol Clin 1992; 10: 456-461.
4. Philippon, A., Arlet, G., Lagrange, P.H. Origin and impact of plasmid-mediated extended-spectrum beta-lactamases. Eur J Clin Microbiol Infect Dis 1994; 13: S17-S29.
5. Asensio, A., Oliver, A., González-Diego, P. y cols. Outbreak of a multiresistant Klebsiella pneumoniae strain in an intensive care unit: Antibiotic use as risk factor for colonization and infection. Clin Infect Dis 2000; 30: 55-60.
6. Babini, G.S., Livermore, D.M. Antimicrobial resistance amongst Klebsiella spp. collected from intensive care units in Southern and Western Europe in 1997-1998. J Antimicrob Chemother 2000; 45: 183-189.
7. Gniadkouwski, M. Evolution and epidemiology of extended-spectrum beta-lactamases (ESBLs) and ESBL-producing microorganisms. Clin Microbiol Infect 2001; 7: 597-608.
8. Winokur, P.L., Cantón, R., Casellas, J.M., Legakis, N. Variations in the prevalence of strains expressing an extended-spectrum beta-lactamase phenotype and characterization of isolates from Europe, the Americas, and the Western Pacific Region. Clin Infect Dis 2001; 32: S94-103.
9. Coque, T.M., Oliver, A., Pérez-Díaz, J.C., Baquero, F., Cantón, R. Genes encoding TEM-4, SHV-2, and CTX-M-10 extended-spectrum beta-lactamases are carried by multiple Klebsiella pneumoniae clones in a single hospital (Madrid, 1989 to 2000). Antimicrob Agents Chemother 2002; 46: 500-510.
10. Ayyagari, A., Bhargava, A. Beta-lactamases and their clinical significance (a mini review). Hospital Today 2001; 6: 1-6.
11. Bermejo, J., Lesnaberes, P., Arnesi, N. y cols. Factures de riesgo asociados con las infecciones debidas a Klebsiella pneumoniae resistentes a ceftacidima. Enferm Infecc Microbiol Clin 2003; 21: 72-76.
12. Pujol, M., Peña, C. El significado clínico de las betalactamasas de espectro extendido. Enferm Infecc Microbiol Clin 2003; 21: 69-71.
13. Sabaté, M., Miró, E., Navarro, F. y cols. Beta-lactamases Involved in resistance to broad-spectrum cephalosporins in Escherichia coli and Klebsiella spp. clinical isolates collected between 1994 and 1996, in Barcelona (Spain). J Antimicrob Chemother 2002; 49: 989-997.
14. Miró, E., del Cuerpo, M., Navarro, F., Sabaté, M., Mirelis, B., Prats, G. Emergence of clinical isolates of Escherichia coli with decreased susceptibility to cefiazidime and synergic effect with co-amoxyclav due to SHV-1 hyperproduction. J Antimicrob Chemother 1998; 42: 535-538.
15. Mirelis, B., Navarro, F., Miró, E., Mensa, R.J., Coll, P., Prats, G. Community transmission of extended-spectrum beta-lactamase. Emerg Infect Dis 2003; 8: 1024-1025.
16. Hernández, J.R., Pascual, A., Cantón, R., Martínez-Martínez, L. y Grupo de Estudio de Infección Hospitalaria (GEIH). Escherichia coli y Klebsiella pneumoniae productores de betalactamasas de espectro extendido en hospitales españoles (Proyecto GEIH-BLEE 2000). Enferm Infecc Microbiol Clin 2003; 21: 77-82.
17. Peña, C., Pujol, M., Ardanuy, C. y cols. Clinical and molecular epidemiology of a large outbreak due to extended-spectrum betalactamases producing Klebsiella pneumoniae. Impact of third-generation cephalosporins restriction in its control. 36th ICCAC, New Orleans, Louisiana, USA, 1996.
18. Peña, C., Pujol, M., Ardanuy, C. y cols. Epidemiology and successful control of a large outbreak due to Klebsiella pneumoniae producing extended-spectrum beta-lactamases. Antimicrob Agents Chemother 1998; 42: 53-58.
19. Peña, C., Pujol, M., Ardanuy, C. y cols. An outbreak of hospital-acquired Klebsiella pneumoniae bacteraemia, including strains producing extended-spectrum beta-lactamase. J Hosp Infect 2001; 47: 53-59.
20. Rodríguez-Baño, J., Navarro, M.D., Romero L. y cols. Epidemiology and clinical features of infections caused by extended-spectrum beta-lactamase-producing Escherichia coli in nonhospitalized patients. J Clin Microbiol 2004; 42: 1089-1094.
21. Prats, G., Mirelis, B., Miró, E. y cols. Cephalosporin-resistant Escherichia coli among summer camp attendees with salmonellosis. Emerg Infect Dis 2003; 9: 1273-1280.
22. Sanz-Rodríguez, C., Baquero, F., Cercenado, E. y cols. Patrones de sensibilidad antimicrobiana de Enterobacteriaceae inducibles y productoras de BLEE causantes de infección intraabdominal en España: Resultados del estudio SMART 2003. Rev Esp Quimioterap 2005; 18 (Supl. 1): 135.
23. Lautenbach, E., Patel, J.B., Bilker, W.B., Edelstein, PH., Fishman, N.O. Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: Risk factors for infection and impact of resistance on outcomes. Clin Infect Dis 2001; 32: 1162-1171.
24. Burges, D.S., Hall, R.G., Lewis, J.S., Jorgensen, J.H., Patterson, J.E. Clinical and microbiologic analysis of a hospital's extended-spectrum-beta- lactamase-producing isolates over a 2 years period. Pharmacotherapy 2003; 23: 1232-1237.
25. Paterson, D.L., Mulazimoglu, L., Casellas, J.M. y cols. Epidemiology of ciprofloxacin resistance and its relationship to extended-spectrum beta-lactamase production in Klebsiella pneumoniae isolates causing bacteremia. Clin Infect Dis 2000; 30: 473-478.
26. Paterson, D.L., Ko, W.C., Von Gottberg, A. y cols. Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum beta-lactamases: Implications for the clinical microbiology laboratory. J Clin Microbiol 2001; 39: 2206-2212.
27. Tellado, J.M., Sitjes-Serra, A., Barcenilla, F. y cols. Pautas de tratamiento antibiótico empírico en las infecciones intraabdominales. Rev Esp Quimioterap 2005; 18: 179-186.